FAM225A and hepatocellular carcinoma: These results supplied with a novel insight into the molecular mechanism of chemoresistance and indicated targeting the FAM225A/miR-130a-5p/CCNG1 regulatory axis might offer a new strategy for treating sorafenib resistance in HCC.